Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miRNA-6883 lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- SMURF Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
miRNA-6883 lipid nanoparticles are an experimental RNA-based therapeutic consisting of microRNA 6883-5p (miR-6883) encapsulated within a lipid nanoparticle (LNP) delivery system. Developed by SMURF Therapeutics in collaboration with Brown University, the drug functions by silencing the expression of cyclin-dependent kinases 4 and 6 (CDK4/6). This inhibition triggers the degradation of Hypoxia-Inducible Factor 1α (HIF1α) via the E3 ubiquitin ligase SMURF2, effectively targeting both cell cycle progression and hypoxia-driven survival pathways in cancer cells. Preclinical data presented at AACR 2026 demonstrated significant anti-tumor activity in colorectal and breast cancer models, particularly when combined with MEK inhibitors or ferroptosis-inducing agents.
- Other names
- miR-6883miR6883miR 6883microRNA 6883-5p lipid nanoparticlesmicroRNA6883-5p lipid nanoparticlesmicroRNA-6883-5p lipid nanoparticlesmiR-6883-5pmiR6883-5pmiR 6883-5p
02
Targets
HIF1A (Hypoxia-inducible factor 1-alpha)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on miRNA-6883 lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miRNA-6883 lipid nanoparticles.